Outcome and predictive factors in uterine carcinosarcoma using postoperative radiotherapy: a Rare Cancer Network study

Basit Öğe Kaydı
dc.contributor.authorZwahlen, Daniel R.
dc.contributor.authorSchick, Ulrike
dc.contributor.authorBolukbasi, Yasemin
dc.contributor.authorThariat, Juliette
dc.contributor.authorAbdah-Bortnyak, Roxolyana
dc.contributor.authorKuten, Abraham
dc.contributor.authorIgdem, Sefik
dc.contributor.authorCaglar, Hale
dc.contributor.authorOzsaran, Zeynep
dc.contributor.authorLoessl, Kristina
dc.contributor.authorBelkaaloul, Kaouthar Khanfir
dc.contributor.authorVillette, Sylviane
dc.contributor.authorVees, Hansjorg
dc.date.accessioned2019-10-27T22:58:04Z
dc.date.available2019-10-27T22:58:04Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.description.abstractUterine carcinosarcomas (UCS) are rare tumors. Consensus regarding therapeutic management in non-metastatic disease is lacking. This study reports on outcome and predictive factors when using postoperative radiotherapy. We analyzed a retrospective analysis in 124 women treated between 19872007 in the framework of the Rare-Cancer-Network. Median follow-up was 27 months. Postoperative pelvic EBRT was administered in 105 women (85%) and 92 patients (74%) received exclusive or additional vaginal brachytherapy. Five-year overall survival (OS), disease-free survival (DFS), cancer specific survival (CSS) and locoregional control (LRC) were 51.6% (95% CI 35-73%), 53.7% (39-71%), 58.6% (38-74%) and 48% (38-67%). Multivariate analysis showed that external beam radiation therapy (EBRT) >50Gy was an independent prognostic factor for better OS (P=0.03), CSS (P=0.02) and LRC (P=0.01). Relative risks (RR) for better OS (P=0.02), DFS (P=0.04) and LRC (P=0.01) were significantly associated with younger age (<= 60 years). Higher brachytherapy (BT)-dose (>9Gy) improved DFS (P=0.04) and LRC (P=0.008). We concluded that UCS has high systemic failure rate. Local relapse was reduced by a relative risk factor of over three in all stages of diseases when using higher doses for EBRT and brachytherapy. Postoperative RT was most effective in UCS stage I/II-diseases.en_US
dc.identifier.doi10.4081/rt.2016.6052en_US
dc.identifier.endpage48en_US
dc.identifier.issn2036-3605
dc.identifier.issn2036-3613
dc.identifier.issue2en_US
dc.identifier.pmid27441069en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage42en_US
dc.identifier.urihttps://doi.org/10.4081/rt.2016.6052
dc.identifier.urihttps://hdl.handle.net/11454/51423
dc.identifier.volume8en_US
dc.identifier.wosWOS:000379084900001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPagepress Publen_US
dc.relation.ispartofRare Tumorsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCarcinosarcomaen_US
dc.subjectuterine malignanciesen_US
dc.subjectradiotherapyen_US
dc.subjectbrachytherapyen_US
dc.subjecttoxicityen_US
dc.titleOutcome and predictive factors in uterine carcinosarcoma using postoperative radiotherapy: a Rare Cancer Network studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu